IDEAS home Printed from https://ideas.repec.org/r/nbr/nberwo/21012.html
   My bibliography  Save this item

Preventives Versus Treatments

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Joseph P. Newhouse, 2021. "An Ounce of Prevention," Journal of Economic Perspectives, American Economic Association, vol. 35(2), pages 101-118, Spring.
  2. Michal Fabinger & E. Glen Weyl, 2018. "Functional Forms for Tractable Economic Models and the Cost Structure of International Trade," CIRJE F-Series CIRJE-F-1092, CIRJE, Faculty of Economics, University of Tokyo.
  3. Eswaran, Mukesh & Gallini, Nancy, 2016. "Rescuing the Golden Age of Antibiotics: Can Economics Help Avert the Looming Crisis?," Economics working papers nancy_gallini-2016-9, Vancouver School of Economics, revised 04 Jul 2016.
  4. Goodkin-Gold, Matthew & Kremer, Michael & Snyder, Christopher M. & Williams, Heidi, 2022. "Optimal vaccine subsidies for endemic diseases," International Journal of Industrial Organization, Elsevier, vol. 84(C).
  5. Christopher M. Snyder & Victor J. Tremblay, 2018. "Introduction to the Special Issue on “The Intersection Between Industrial Organization and Healthcare Economics”," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 1-6, August.
  6. Michal Fabinger & E. Glen Weyl, 2016. "The Average-Marginal Relationship and Tractable Equilibrium Forms," CIRJE F-Series CIRJE-F-1028, CIRJE, Faculty of Economics, University of Tokyo.
  7. Agarwal, Ruchir & Gaule, Patrick, 2022. "What drives innovation? Lessons from COVID-19 R&D," Journal of Health Economics, Elsevier, vol. 82(C).
  8. Kjell Hausken & Mthuli Ncube, 2020. "Game theoretic analysis of persons, the pharmaceutical industry, and donors in disease contraction and recovery," Palgrave Communications, Palgrave Macmillan, vol. 7(1), pages 1-17, December.
  9. Matthew Goodkin-Gold & Michael Kremer & Christopher M. Snyder & Heidi L. Williams, 2020. "Optimal Vaccine Subsidies for Endemic and Epidemic Diseases," NBER Working Papers 28085, National Bureau of Economic Research, Inc.
  10. Dominique Foray & Gaetan de Rassenfosse & George Abi Younes & Charles Ayoubi & Omar Ballester & Gabriele Cristelli & Matthias van den Heuvel & Ling Zhou & Gabriele Pellegrino & Patrick Gaulé & Elizab, 2020. "COVID-19: Insights from Innovation Economists," Working Papers 10, Chair of Science, Technology, and Innovation Policy.
    • Younes, George Abi & Ayoubi, Charles & Ballester, Omar & Cristelli, Gabriele & de Rassenfosse, Gaetan & Foray, Dominique & Gaule, Patrick & Pellegrino, Gabriele & van den Heuvel, Matthias & Webster, B, 2020. "COVID-19_Insights from Innovation Economists," SocArXiv b5zae, Center for Open Science.
  11. Kremer, Michael & Williams, Heidi & Snyder, Christopher & Goodkin-Gold, Matthew, 2020. "Optimal Subsidies for Prevention of Infectious Disease," CEPR Discussion Papers 15433, C.E.P.R. Discussion Papers.
  12. Das, Jishnu, 2020. "Zen and the art of experiments: A note on preventive healthcare and the 2019 nobel prize in economics," World Development, Elsevier, vol. 127(C).
  13. Kremer, Michael, 2018. "Worst-Case Bounds on R&D and Pricing Distortions: Theory and Disturbing Conclusions if Consumer Values Follow the World Income," CEPR Discussion Papers 13241, C.E.P.R. Discussion Papers.
  14. Eswaran, Mukesh & Gallini, Nancy, 2017. "Can Competition Extend the Golden Age of Antibiotics?," Microeconomics.ca working papers -2017-9, Vancouver School of Economics, revised 19 Oct 2017.
  15. Kremer, Michael & Snyder, Christopher, 2018. "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global D," CEPR Discussion Papers 12751, C.E.P.R. Discussion Papers.
  16. Kjell Hausken & Mthuli Ncube, 2021. "Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation," Health Economics Review, Springer, vol. 11(1), pages 1-14, December.
  17. David E. Bloom & Michael Kuhn & Klaus Prettner, 2022. "Modern Infectious Diseases: Macroeconomic Impacts and Policy Responses," Journal of Economic Literature, American Economic Association, vol. 60(1), pages 85-131, March.
  18. Michal Fabinger & E. Glen Weyl, 2016. "Functional Forms for Tractable Economic Models and the Cost Structure of International Trade," Papers 1611.02270, arXiv.org, revised Aug 2018.
  19. Carrasco, Vinicius & Farinha Luz, Vitor & Kos, Nenad & Messner, Matthias & Monteiro, Paulo & Moreira, Humberto, 2018. "Optimal selling mechanisms under moment conditions," Journal of Economic Theory, Elsevier, vol. 177(C), pages 245-279.
  20. Michael Kremer & Christopher M. Snyder, 2018. "Worst-Case Bounds on R&D and Pricing Distortions: Theory with an Application Assuming Consumer Values Follow the World Income Distribution," NBER Working Papers 25119, National Bureau of Economic Research, Inc.
  21. Schankerman, Mark & Galasso, Alberto, 2020. "Licensing Life-Saving Drugs for Developing Countries: Evidence from the Medicines Patent Pool," CEPR Discussion Papers 15544, C.E.P.R. Discussion Papers.
  22. Kjell Hausken & Mthuli Ncube, 2017. "Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS," Health Economics Review, Springer, vol. 7(1), pages 1-12, December.
  23. Ohid Yaqub, 2018. "Variation in the dynamics and performance of industrial innovation: what can we learn from vaccines and HIV vaccines?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 27(1), pages 173-187.
  24. Postigo, Antonio, 2023. "The Economics and Actors in Vaccine Research and Development," EconStor Open Access Book Chapters, in: From Lab to Jab: Improving Asia and the Pacific’s Readiness to Produce and Deliver Vaccines, pages 17-42, ZBW - Leibniz Information Centre for Economics.
  25. Michael Kremer & Christopher M. Snyder, 2018. "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 235-273, August.
  26. Daniel Bauer & Darius Lakdawalla & Julian Reif, 2018. "Mortality Risk, Insurance, and the Value of Life," NBER Working Papers 25055, National Bureau of Economic Research, Inc.
  27. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
  28. Hausken, Kjell & Ncube, Mthuli, 2015. "Policy-Makers, the International Community and People Living with HIV: The Need for New Commitment Mechanisms," UiS Working Papers in Economics and Finance 2015/6, University of Stavanger.
  29. Younes, George Abi & Ayoubi, Charles & Ballester, Omar & Cristelli, Gabriele & de Rassenfosse, Gaetan & Foray, Dominique & Gaule, Patrick & van den Heuvel, Matthias & Webster, Beth & Zhou, Ling, 2020. "COVID-19: Insights from Innovation Economists (with French executive summary)," SocArXiv 65pgr, Center for Open Science.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.